BioNexus Gene Lab Corp. (BGLC) Operating margin 2018–2025
BioNexus Gene Lab Corp. (BGLC) operating margin by fiscal year — reported operating income divided by reported revenue.
-39.9%FY2025 · since FY2018: 28.2% → -39.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -39.9% | -23.4 pp |
| FY2024 | -16.5% | +10.0 pp |
| FY2023 | -26.5% | -23.9 pp |
| FY2022 | -2.7% | -10.6 pp |
| FY2021 | 7.9% | -3.3 pp |
| FY2020 | 11.2% | +228.4 pp |
| FY2019 | -217.2% | -245.4 pp |
| FY2018 | 28.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Gross marginBGLC Operating incomeBGLC Operating cash flowBGLC Free cash flowBGLC Capital expendituresBGLC Return on equityBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Total liabilitiesBGLC Shareholders’ equityBGLC overview →